Common adverse events reported for all beta-lactamase inhibitors included hematologic disorders (myelosuppression, hemolysis, thrombocytopenia), hypersensitivity reactions (anaphylaxis, DRESS, SJS, TEN), risk of emergent infections (Clostridium difficile, Klebsiella, Candida), organ dysfunction (hepatic, renal, multiple organ), and neurological issues (encephalopathy, epilepsy, delirium). The gene discussed is LACTB; the disease is hemolysis.